The research compared diabetic animal models that were designed to express different variants of Hp. An animal model that expresses the Hp2 variant shows greater vascular damage, than an animal model that expresses the Hp1 variant of the protein.
HaptoGuard intends to examine the efficacy of BXT-51072 applied to the diabetic, Hp2 mouse. Hp2 in the context of diabetes identifies patients at increased risk of death and heart failure following heart attack. Positive efficacy results from such a study would further support the Company’s choice to develop BXT-50172 in cardiovascular disease.